| Price | $1.77 |
| Year Range | $1.5 – $5 |
| Market Cap | $22M |
| Industry | Biotechnology |
What Is Tvardi Therapeutics’s AI Stock Analysis?
Tvardi Therapeutics’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Tvardi Therapeutics’s momentum in near-real time.
Tvardi Therapeutics (TVRD) has an AltIndex AI Score of 51/100, currently a Hold signal. The AI Score distills Tvardi Therapeutics's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Tvardi Therapeutics’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Tvardi Therapeutics — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving TVRD’s AI Score?
Fundamentals
Revenue for the last quarter was $0. This is equal to the revenue of the quarter before it, showing stability. However, compared to the same quarter last year, there is a decrease of 100.00%, which may be a cause for concern. Net income for the last quarter was $-6.8M. This is an increase of -6.47% compared to the quarter before it, which is a positive sign of growth. However, compared to the same quarter last year, there is a decrease of 38.69%, which may be a cause for concern. Ebitda for the last quarter was $-6.8M. This is an increase of -6.16% compared to the quarter before it, which is a positive sign of growth. However, compared to the same quarter last year, there is a decrease of 237.67%, which may be a cause for concern.
See Tvardi Therapeutics’s earnings and insider transactions.
Technicals
Today's stock price is $1.77. This represents a decrease of 46.53% compared to a month ago, which may be concerning in the short-term. However, compared to a year ago, there is a decrease of 92.56%, which could be a cause for long-term concern. The trend is bearish. The current SMA10 is $1.86, which is lower than the previous SMA10 of $1.88. This suggests a potential downward trend in price movement. The RSI is 92, indicating a potentially overbought (bearish) condition.
See the full technical analysis and price prediction.
Alternative data
Tvardi Therapeutics has an estimate of 4,000 visitors to their webpage. The number of visitors is up by 300% in the last couple of months, a bullish trend as this can indicate can increase in customers.
Explore Tvardi Therapeutics’s job postings, web traffic and app downloads.
Sentiment & social
The sentiment for the stock on various stock forums is very high, a positive sign. Tvardi Therapeutics has 130 followers on their Twitter page. The number of followers is up by 4% in the last couple of months, indicating an increased interest in the company.
Track Tvardi Therapeutics’s market sentiment.
Frequently Asked Questions: Tvardi Therapeutics AI Stock Analysis
Tvardi Therapeutics's AltIndex AI Score is 51/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Tvardi Therapeutics a Hold (51/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Tvardi Therapeutics — company overview, fundamentals, technicals and alternative data, with a recommendation. See the TVRD AI Score or sign up to read the full thesis.
